Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
You can't cure sleep apnea but you can manage it — doctors explain how
Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
How eating more cheese may be the secret to getting better sleep
There’s gouda news for cheese lovers. A recent study found cheese eaters are less likely to have sleep apnea than their dairy ...
FDA approves first ever medication for obstructive sleep apnea — here's what that means
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
Optical imaging technique offers more precise diagnosis of sleep apnea
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
Study confirms brief apnea risk after vaccination of hospitalized preemies
Hospitalized premature infants who received recommended two-month vaccinations had an increased risk of a short episode of apnea, but no serious complications arose, according to a study led by Duke ...
Rolling Out2d
How a sleep mask for apnea reduces high blood pressure risk
Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...
Healio1d
The year in obesity: New data on semaglutide and tirzepatide, sarcopenic obesity and more
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
PharmiWeb4d
Global Excessive Daytime Sleepiness Market is expected to reach USD 12.39 Billion by 2033 with a fast-expanding CAGR of 8.8%
The excessive daytime sleepiness market drowsiness was projected to be worth USD 4.9 billion in 2022. With an expected CAGR of 8.8% from 2023 to 2033, this market is expected to earn USD 5.33 billion ...